Analysis Plan: Study to Measure the Cost of CHAMPUS-Eligible Participants in Southwest Oncology Group NCI Cooperative Program Cancer Clinical Trials 1988-1996: Technical Report No. 1.
Interim rept. Oct 88-Sep 96,
CENTER FOR HEALTHCARE EDUCATION AND STUDIES FORT SAM HOUSTON TX
Pagination or Media Count:
The National Cancer Institutes Division of Cancer Treatment, Diagnosis, and Centers DCTDC has initiated effort to expand clinical trial participation by proposing coverage agreement of NCI clinical trial participants with various third party payers. An agreement was signed with the Department of Defense DOD to allow patients who are beneficiaries of TRICAKECHAMPUS to participate in, and be reimbursed for, NCI-sponsored clinical cancer treatment trials. This study is a cancer demonstration project pilot study to evaluate the potential cost impact of the NCIDOD agreement. The initial study phase identified CHAMPUS eligible beneficiaries CEBs diagnosed with cancer and enrolled in NCI clinical trials 1988-1996. CEBs treated for cancer of the breast, prostate, colon, lung, leukemia, and lymphoma in phase 2 and 3 adjuvant, advanced recurrent disease trials were identified. The second phase of this study will be to determine the cost of the clinical trials by using TRICARECHAMPUS claims data from resource utilization of inpatient and outpatient ambulatory professional services and institutional costs CEB enrolled in clinical trials will be compared to a non-trial group disease and clinical matched CEB cancer cases.
- Economics and Cost Analysis
- Personnel Management and Labor Relations
- Test Facilities, Equipment and Methods